Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data Analytics & AI · Biostatistics

The Role of Biostatistics in Clinical Research: Responsibilities of the Trial Statistician

Statistical input is not a step performed on the data after a trial has ended; the governing regulatory guideline places a qualified statistician in the trial from the design stage, before any patient is recruited.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published8 October 2026 Last checked8 October 2026 Reading time6 minutes

ICH E9, the harmonised guideline that both the FDA and the EMA require, provides the formal basis for the involvement of a biostatistician in a clinical trial and for its timing. This article sets out what that involvement covers across the trial lifecycle and what the published evidence shows when it is absent.

The regulatory basis for the role

ICH E9, “Statistical Principles for Clinical Trials” (International Council for Harmonisation, 1998; adopted by FDA and EMA), states that statistical methods are essential to the proper design and analysis of a clinical trial, and assigns responsibility for all of a trial’s statistical work to a qualified, experienced trial statistician. This is not merely a recommendation; for a regulated trial, it is the standard that a sponsor is expected to meet.

Distribution of statistical responsibility across the trial lifecycle

Design.Selecting the comparison, endpoint and randomisation method so that the trial is capable of answering its question
Sample size.Calculating the number of patients required to detect a clinically meaningful effect before recruitment opens, rather than after it stalls
The statistical analysis plan (SAP).Pre-specifying every planned analysis before the data are unblinded, so that the analysis cannot be adapted to whatever result appears
Interim monitoring.Working with a Data Safety Monitoring Board on any pre-planned interim look at the data, without unblinding the wider trial team
Final analysis and reporting.Conducting the pre-specified analysis and reporting it in line with CONSORT, including the distinction between pre-specified and exploratory analyses

Consequences of absent statistical involvement

Doug Altman’s widely cited 1994 editorial, “The scandal of poor medical research” (BMJ. 1994;308(6924):283–284), argued that much published medical research at the time was poorly designed and analysed — small or unrepresentative samples, incorrect statistical methods, selective reporting — and noted that few research ethics committees included a statistician and that many journals did little statistical refereeing. More recent direct evidence came from Diaz-Ordaz K, et al. (BMC Med Res Methodol. 2013;13:127), who reviewed 73 cluster-randomised trials and found that trials with a statistician or quantitative methodologist as a co-author were significantly more likely to account properly for clustering in their analysis (adjusted odds ratio 3.1). The same study found that journal endorsement of the CONSORT reporting checklist alone was not associated with better trial quality; the checklist does not substitute for the person applying it.

Diaz-Ordaz et al. 2013: what was associated with handling clustering correctly, and what was not

Factor checkedAdjusted odds ratio95% CIStatistically significant?
Statistician/methodologist as co-author3.11.1–8.7Yes
Statistician co-author (sample size specifically)2.70.5–16.2No
Journal endorses CONSORTNot associated—No

Source: Diaz-Ordaz K, et al. BMC Med Res Methodol. 2013;13:127. 73 cluster-randomised trials reviewed.

Limitations of the available evidence

The Diaz-Ordaz study is observational rather than a randomised comparison of “trials with a statistician” versus “trials without one”; its sample of 73 trials is modest; and two of its own authors are statisticians, which the paper declares as a competing interest. A second outcome in the same study (whether statistician involvement improved the sample-size calculation specifically) was not statistically significant after adjustment. The direction of the evidence is consistent with the premise of ICH E9, but it does not demonstrate that adding a statistician guarantees a better trial.

Frequently asked questions

Before the protocol is finalised, in accordance with ICH E9, because sample size and randomisation decisions are made at that stage and are difficult to correct once recruitment has started.

The International Committee of Medical Journal Editors (ICMJE) authorship criteria apply to a biostatistician in the same way as to any contributor: substantial contribution to the work, drafting or critically revising it, and approval of the final version. A separate short page addresses this question; see the link below.

References

  1. International Council for Harmonisation. "ICH E9: Statistical Principles for Clinical Trials." read 8 October 2026. ICH, 1998 (FDA guidance for industry)
  2. Altman DG. "The scandal of poor medical research." read 8 October 2026. BMJ. 1994;308(6924):283–284
  3. Diaz-Ordaz K, Froud R, Sheehan B, Eldridge S. "A systematic review of cluster randomised trials in residential facilities for older people suggests how to improve quality." read 8 October 2026. BMC Med Res Methodol. 2013;13:127

Each source carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 8). The Role of Biostatistics in Clinical Research: Responsibilities of the Trial Statistician. Pubrica. https://pubrica.com/academy/statistical/the-importance-and-role-of-biostatistics-in-clinical-research/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s biostatisticians join a study at the protocol stage so that the sample size, randomisation and analysis plan are established correctly before recruitment opens, rather than reconstructed afterwards.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Involvement of a biostatistician from the design stage of a trial

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.